dc.contributor
Institut Català de la Salut
dc.contributor
[Saini KS] Covance Inc, Princeton, NJ, USA. East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK. [Lanza C, Romano M] Covance Inc, Princeton, NJ, USA. [de Azambuja E] Institut Jules Bordet, Brussels, Belgium. Université Libre de Bruxelles (U.L.B), Brussels, Belgium. [Cortes J] IOB Institute of Oncology, Quiron Group, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medica Scientia Innovation Research, Ridgewood, NJ, USA. [de Las Heras B] Covance Inc, Princeton, NJ, USA. Madrid Medical Doctors Association, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Lanza, Carlo
dc.contributor.author
Romano, Marco
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
de las Heras, Begoña
dc.contributor.author
Saini, Kamal S.
dc.contributor.author
de Azambuja, Evandro
dc.date.accessioned
2025-10-25T05:37:32Z
dc.date.available
2025-10-25T05:37:32Z
dc.date.issued
2021-10-21T09:29:58Z
dc.date.issued
2021-10-21T09:29:58Z
dc.identifier
Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020 Sep;123:694–697.
dc.identifier
https://hdl.handle.net/11351/6429
dc.identifier
10.1038/s41416-020-0948-x
dc.identifier
000542071100001
dc.identifier.uri
http://hdl.handle.net/11351/6429
dc.description.abstract
Desenvolupament de fàrmacs; Infecció viral
dc.description.abstract
Desarrollo de fármacos; Infección viral
dc.description.abstract
Drug development; Viral infection
dc.description.abstract
Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
British Journal of Cancer;123
dc.relation
https://doi.org/10.1038/s41416-020-0948-x
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
COVID-19 (Malaltia)
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Drug Development::Drug Repositioning
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::desarrollo de medicamentos::nuevas indicaciones de medicamentos
dc.title
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
